**Supplementary appendix.**

Supplementary tables.

Table S1. ICU admission, mechanical ventilation, death and composite outcome.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | ICU admission | Mechanical ventilation | Death | ICU admission, mechanical ventilation and death. |
| Group | Within day 15 | Within day 30 | Within day 15 | Within day 30 | Within day 15 | Within day 30 | Within day 15 | Within day 30 |
| Control | 5 | 5 | 3 | 3 | 2 | 4 | 7 | 9 |
| telmisartan | 4 | 4 | 1 | 1 | 2 | 2 | 6 | 6 |

Table S2. Patients characteristics and causes of death.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Patient id | Group | Severity at admission  | Age | Comorbidities | Days after randomization | Cause of death |
| 17 | control | No need of supplemental O2 | 84 | None | 22 days | sepsis |
| 18 | control | Need of supplemental O2 | 75 | Hypertension | 10 days | respiratory insufficiency |
| 35 | control | Need of supplemental O2 | 94 | Cognitive impairment | 27 days | respiratory insufficiency |
| 61 | control | Need of supplemental O2 | 81 | Hypertension, stroke, cognitive impairment | 13 days | respiratory insufficiency |
| 39 | telmisartan | Need of high flow supplemental O2 | 69 | Hypertension, stroke, peripheral vascular disease, heart failure, arrythmia. | 4 days | fulminant myocarditis |
| 40 | telmisartan | No need of supplemental O2 | 89 | Dyslipemia, stroke, arrythmia, peripheral vascular disease. | 15 days | sepsis |

Table S3. Blood pressure.

|  |
| --- |
| Blood pressure |
|  | Day 1 | Day 5 | Day 8 |
|  | SystolicMean ± SD (n) | DiastolicMean ± SD (n) | SystolicMean ± SD (n) | DiastolicMean ± SD (n) | SytolicMean ± SD (n) | DiastolicMean ± SD (n) |
| Control | 120.5 ± 18.2 (37) | 71.6±9.7(37) | 119.0 ± 12.1 (33) | 70.4±7.1(33) | 118.1±16.6(24) | 70.6±10.7(24) |
| telmisartan | 121.3±12.8(40) | 72.6±10.6(40) | 118.7±12.1(38) | 70.4±7.7(38) | 115.0±15.4(22) | 69.5±10.0(22) |

Table S4. LDH and hematological indices. Differences in LDH values were not statistically significant.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | control (mean ± SD, [n]) | telmisartan(mean ± SD, [n]) |
| LDH (UI/L) | Day 5 | 511.0 ± 196.7 [35] | 452.7 ± 159.6 [28] |
|  | Day 8 | 501.8 ± 209.5 [15] | 393.4 ± 60.7 [12] |
|  |  |  |  |
| White blood cell count (103/µL) | Day 5 | 6.56 ± 2.72 [28] | 6.73 ± 2.88 [31] |
|  | Day 8 | 7.91 ± 2.73 [16] | 5.72 ± 1.59 [13] |
|  |  |  |  |
| Lymphocyte count (103/µL) | Day 5 | 1.32 ± 0.86 [28]  | 1.72 ± 0.81 [29] |
|  | Day 8 | 1.28 ± 0.92 [13] | 1.75 ± 0.74 [13] |
|  |  |  |  |
| Neutrophil count (103/µL)  | Day 5 | 4.61 ± 2.67 [28] | 4.53 ± 3.07 [29] |
|  | Day 8 | 5.87 ± 2.71 [13] | 3.07 ± 1.72 [13] |
|  |  |  |  |
| Neutrophil to lymphocyte ratio | Day 5 | 5.19 ± 6.33 [28] | 4.12 ± 5.12 [29] |
|  | Day 8 | 6.69 ± 5.63 [13] | 2.31 ± 2.67 [13] |
|  |  |  |  |
| Eosinophil count (103/µL)  | Day 5 | 0.056 ± 0.07 [27] | 0.099 ± 0.136 [29] |
|  | Day 8 | 0.159 ± 0.167 [13] | 0.135 ± 0.108 [13] |
|  |  |  |  |
| Platelets | Day 5 | 235.9 ± 96.1 [28] | 305 ± 144.9 [31] |
|  | Day 8 | 315.4 ± 101.3 [16] | 321.3 ± 124.1 [13] |

Supplementary figures.

Figure S1. Lactate dehydrogenase (LDH, a), white blood cells (WBC, b), neutrophils (c), lymphocytes (d), neutrophil to lymphocyte ratio (e), eosinophils (f) and platelets (g) at 1, 5 and 8 days in control and telmisartan group. All points represent mean ± SEM

